Company research
Theriva Biologics, Inc.
CIK 894158Updated Sep 24, 2026
SecurityTOVX · NYSE_AMERICAN · equity
Name history
Synthetic Biologics, Inc. · through Oct 12, 2022ADEONA PHARMACEUTICALS, INC. · through Feb 17, 2012PIPEX PHARMACEUTICALS, INC. · through Oct 16, 2008SHEFFIELD PHARMACEUTICALS INC · through Dec 8, 2006SHEFFIELD MEDICAL TECHNOLOGIES INC · through May 14, 1997
TOVX price & chart
Loading TradingView…
AMEX:TOVX on TradingView ↗About the company
We are a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. As a result of the acquisition in March 2022 of Theriva Biologics, S.L. (“VCN”, formerly named VCN Biosciences, S.L.), described in more detail below (the “Acquisition”), we began transitioning our strategic focus to oncology, which is now our primary focus, through the development of VCN’s new oncolytic adenovirus platform designed for intravenous and intravitreal delivery to trigger tumor cell death, to improve access of co-administered cancer therapies to the tumor, and to promote a robust and sustained anti-tumor response by the patient’s immune system. Our lead product candidate, VCN-01, a clinical stage oncolytic human adenovirus that is modified for tumor-selective replication and to express an enzyme, PH20 hyaluronidase, is currently being evaluated in a Phase 2 clinical study for the treatment of pancreatic cancer (“Virage”), and has recently been used to treat patients in a Phase 1 clinical study for the treatment of retinoblastoma, and Phase 1 clinical studies for the treatment of other solid tumors including head and neck squamou…
In the news
No coverage from other publishers is available.
Recent filings
S-8 filing
10-Q filing
Results of Operations and Financial Condition
Items 2.02, 9.01
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Submission of Matters to a Vote of Security Holders
Items 5.02, 5.07, 9.01
Show 5 more recent filings
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
DEF 14A filing
ARS filing
PRE 14A filing
Regulation FD Disclosure · Other Events
Items 7.01, 8.01, 9.01
Financials
FY 2025 · USDSource
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 38,239,000Source | 35,352,000Source | 55,219,000Source | 80,642,000Source |
| Property, Plant and Equipment, NetUSD | 222,000Source | 270,000Source | 422,000Source | 285,000Source |
| GoodwillUSD | — | 0Source | 5,700,000Source | 6,218,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 19,619,000Source | 17,358,000Source | 19,755,000Source | 17,840,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 13,056,000Source | 11,609,000Source | 23,177,000Source | 52,266,000Source |
| Assets, CurrentUSD | 17,467,000Source | 16,281,000Source | 27,403,000Source | 54,888,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,060,000Source | 1,444,000Source | 2,414,000Source | 2,622,000Source |
| Operating Lease, Right-of-Use AssetUSD | 803,000Source | 1,272,000Source | 1,759,000Source | 1,292,000Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 22,856,000Source | 16,285,000Source | 15,522,000Source | 18,421,000Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 34,000Source | 3,000Source | 18,000Source | 16,000Source |
| Retained Earnings (Accumulated Deficit)USD | -358,710,000Source | -334,971,000Source | -309,318,000Source | -280,034,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 755,000Source | -1,178,000Source | 32,000Source | -1,261,000Source |
| Stockholders' Equity Attributable to ParentUSD | — | — | — | 62,221,000Source |
| Additional Paid in Capital, Common StockUSD | 373,592,000Source | 355,501,000Source | 346,519,000Source | 343,500,000Source |
| Liabilities and EquityUSD | 38,239,000Source | 35,352,000Source | 55,219,000Source | 80,642,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 10,014,000Source | 7,585,000Source | 6,738,000Source | 12,419,000Source |
| Operating Lease, Liability, CurrentUSD | 549,000Source | 539,000Source | 487,000Source | 128,000Source |
| Accounts Payable, CurrentUSD | 1,014,000Source | 859,000Source | 770,000Source | 1,003,000Source |
| Operating Lease, Liability, NoncurrentUSD | 352,000Source | 873,000Source | 1,442,000Source | 1,298,000Source |
| Deferred Income Tax Liabilities, NetUSD | — | — | — | 2,293,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | 6,276,000Source | 3,368,000Source | 2,995,000Source | 1,987,000Source |
| Long-term DebtUSD | 1,671,000Source | 92,000Source | 162,000Source | — |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | -23,739,000Source | -25,653,000Source | -18,349,000Source | -19,685,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 108,000Source | 137,000Source | 135,000Source | 85,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 654,000Source | 671,000Source | 552,000Source | 475,000Source |
| Changes in operating assets and liabilities: | ||||
| Increase (Decrease) in Accounts PayableUSD | 69,000Source | 123,000Source | -157,000Source | -385,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | -1,640,000Source | — |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -16,669,000Source | -16,937,000Source | -18,996,000Source | -19,082,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -35,000Source | -1,000Source | -202,000Source | -4,396,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 35,000Source | 1,000Source | 202,000Source | 116,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 18,193,000Source | 5,496,000Source | 625,000Source | -1,930,000Source |
| Repayments of Long-term DebtUSD | — | 67,000Source | 75,000Source | 1,376,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 1,397,000Source | -11,574,000Source | -18,606,000Source | -25,408,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 13,102,000Source | 11,705,000Source | 23,279,000Source | 41,885,000Source |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | -92,000Source | -132,000Source | -33,000Source | -32,000Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 25,000Source | -4,000Source | 3,000Source | -41,000Source |
| Gain (Loss) on Disposition of AssetsUSD | 1,000Source | — | — | — |
| General and Administrative ExpenseUSD | 15,447,000Source | 7,396,000Source | 7,120,000Source | 9,858,000Source |
| GoodwillUSD | — | 0Source | 5,700,000Source | 5,525,000Source |
| Goodwill, Impairment LossUSD | — | 5,594,000Source | — | — |
| Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)USD | 0Source | 1,325,000Source | — | — |
| Income Tax Expense (Benefit)USD | — | 0Source | -1,640,000Source | -1,425,000Source |
| Investment Income, InterestUSD | 287,000Source | 697,000Source | 1,439,000Source | 512,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,349,000Source | -19,685,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,249,000Source | -25,653,000Source | -18,349,000Source | -20,025,000Source |
| Nonoperating Income (Expense)USD | 312,000Source | 693,000Source | 1,442,000Source | 471,000Source |
| Operating ExpensesUSD | 24,051,000Source | 26,346,000Source | 21,431,000Source | 21,581,000Source |
| Proceeds from Issuance of Common StockUSD | — | — | — | 0Source |
| Proceeds from Issuance of Long-term DebtUSD | 1,507,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | 0Source | 0Source | 0Source | 0Source |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -24,051,000Source | -26,346,000Source | -21,431,000Source | -21,581,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -23,739,000Source | -25,653,000Source | -19,989,000Source | -21,110,000Source |
| Income Tax Expense (Benefit)USD | — | 0Source | -1,640,000Source | -1,425,000Source |
| Net Income (Loss) Attributable to Noncontrolling InterestUSD | — | — | — | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | -18,349,000Source | -19,685,000Source |
| Earnings Per Share, BasicUSD per share | -2.08Source | -19.03Source | -1.14Source | -1.31Source |
| Earnings Per Share, DilutedUSD per share | -2.08Source | -19.03Source | -1.14Source | -1.31Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 12,140,697Source | 1,348,126Source | 16,107,014Source | 15,327,328Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 12,140,697Source | 1,348,126Source | 16,107,014Source | 15,327,328Source |
| Additional Financial Items | ||||
| Foreign Currency Transaction Gain (Loss), before TaxUSD | 25,000Source | -4,000Source | 3,000Source | -41,000Source |
| General and Administrative ExpenseUSD | 15,447,000Source | 7,396,000Source | 7,120,000Source | 9,858,000Source |
| Goodwill, Impairment LossUSD | — | 5,594,000Source | — | — |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -15,020,000Source | -7,641,000Source | -8,568,000Source | — |
| Interest Expense, DebtUSD | 61,000Source | — | — | — |
| Investment Income, InterestUSD | 287,000Source | 697,000Source | 1,439,000Source | 512,000Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -25,249,000Source | -25,653,000Source | -18,349,000Source | -20,025,000Source |
| Nonoperating Income (Expense)USD | 312,000Source | 693,000Source | 1,442,000Source | 471,000Source |
| Operating ExpensesUSD | 24,051,000Source | 26,346,000Source | 21,431,000Source | 21,581,000Source |
| Research and Development ExpenseUSD | 8,604,000Source | 12,031,000Source | 14,311,000Source | 11,723,000Source |
Offerings
Registration 333-283722
Filing attachments
tm2622636d1_ex99-1.htm · 8-K · 2026-08-11
EX-99.1 2 tm2622636d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Reports Second Quarter 2026 Operational Highlights and Financial Results - First patients dosed in the VIRAGE2 Phase 2a clinical study evaluating more frequent repeated dosing of VCN-01 (zabilugene almadenorepvec) the goal of which is to improve treatment outcomes in metastatic pancreatic ductal adenocarcinoma (PDAC) patients - - Cash and cash equivalents of $11.3 million as of June 30, 2026; cash runway into Q1…
Read attachment ↗tm2622359d1_ex99-1.htm · 8-K · 2026-08-06
EX-99.1 2 tm2622359d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine the VCN-01 dosing regimen for potential evaluation in a future pivotal Phase 3 clinical trial in metastatic pancreatic ductal adenocarcinoma (PDAC) - - Study bu…
Read attachment ↗tm2619846d1_ex99-1.htm · 8-K · 2026-07-07
EX-99.1 2 tm2619846d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Announces Regulatory Authorization to Proceed with a VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma - VIRAGE2 exploratory study designed to refine dosing regimen to potentially improved outcomes in a future pivotal Phase 3 clinical trial - - Study builds on positive clinical data from t…
Read attachment ↗tm2617564d1_ex99-1.htm · 8-K · 2026-06-11
EX-99.1 2 tm2617564d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Announces Results from VCN-01 Phase 1 Clinical Trial in Head and Neck Cancer Published in Clinical Cancer Research - Prolonged overall survival (OS) was observed in heavily pre-treated refractory Head & Neck Squamous Cell Carcinoma (HNSCC) patients administered IV VCN-01 prior to the immune checkpoint inhibitor durvalumab - - Pharmacokinetic, tissue biopsy, radiomic and transcriptomic results all support the pro…
Read attachment ↗tm2613605d1_ex99-1.htm · 8-K · 2026-05-05
EX-99.1 2 tm2613605d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Reports First Quarter 2026 Operational Highlights and Financial Results - Alignment with the FDA on the Phase 3 trial design of VCN-01 (zabilugene almadenorepvec) for treatment of metastatic pancreatic ductal adenocarcinoma (PDAC) - - Additional data from VIRAGE Phase 2b clinical trial of VCN-01 in metastatic PDAC patients presented at the recent AACR Annual Meeting may reflect an immune-mediated mechanism of ac…
Read attachment ↗tm2612012d1_ex99-1.htm · 8-K · 2026-04-17
EX-99.1 2 tm2612012d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Theriva™ Biologics Announces Upcoming Presentation of Additional Data from the VIRAGE Phase 2b Clinical Trial of VCN-01 in Metastatic Pancreatic Cancer at AACR 2026 Annual Meeting - Tumor reponse, biomarker, and subgroup analyses from the VIRAGE Phase 2b clinical trial support a VCN-01 immune-mediated mode of action and demonstrate improved outcomes in VCN-01 treated patients across multiple subgroups, including patients with liver…
Read attachment ↗